Table 3.

HCC development as a function of scoring system in the training and validation sets.

							Cumulative incidence (% [95% CI])
Score value	No HCC	HCC	Total	sHR	[95% CI]	p value	1 year	2 years	3 years	4 years	5 years
Training set (n = 1,658)
0-5	608 (39.8%)	14 (10.7%)	622 (37.5%)	Ref.			0.3 [0–1.2]	1.1 [0.5–2.3]	1.1 [0.5–2.3]	2.1 [1.0–3.8]	3.7 [2.0–6.1]
6-8	452 (29.6%)	30 (22.9%)	482 (29.1%)	3.38	[1.79; 6.39]	<0.001	0.9 [0.3–2.1]	1.6 [0.7–3.2]	5.4 [3.3–8.1]	7.7 [5.0–11.1]	8.3 [5.4–12.0]
9-16	467 (30.6%)	87 (66.4%)	554 (33.4%)	9.35	[5.30; 16.49]	<0.001	4.6 [3.0–6.7]	9.7 [7.3–12.5]	13.1 [10.2–16.4]	18.8 [14.8–23.3]	21.9 [17.2–27.0]
Validation set (n = 855)
0-5	285 (36.5%)	11 (14.7%)	296 (34.6%)	Ref			0	1.6 [0.5–3.7]	2.0 [0.8–4.4]	2.6 [1.1–5.3]	3.5 [1.5–6.9]
6-8	222 (28.5%)	16 (21.3%)	238 (27.8%)	2.16	[1.01; 4.60]	0.046	1.8 [0.6–4.2]	4.7 [2.4–8.2]	5.9 [3.2–9.8]	7.7 [4.3–12.5]	9.6 [5.1–15.8]
9-16	273 (35.0%)	48 (64.0%)	321 (37.5%)	5.32	[2.82; 10.03]	<0.001	5.9 [3.7–9.0]	10.9 [7.6–14.9]	15.3 [11.2–20.0]	16.7 [12.2–21.7]	21.6 [15.5–28.5]

HCC, hepatocellular carcinoma.